Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Karbinal
Overview
What is Karbinal?
Each 5 mL of Karbinal ER Extended-release Oral Suspension contains carbinoxamine complexed with polistirex equivalent to 4 mg carbinoxamine maleate and the following inactive ingredients: citric acid anhydrous, strawberry-banana flavor, glycerin, high fructose corn syrup, methylparaben, modified food starch, polysorbate 80, polyvinyl acetate, povidone, propylparaben, purified water, sodium metabisulfite, sodium polystyrene sulfonate, sucrose, triacetin, and xanthan gum.
Carbinoxamine maleate is freely soluble in water. The chemical name is 2-[(4-chlorophenyl)-2-pyridinylmethoxy]--dimethylethanamine (Z)-2-butenedioate (1:1), which has the following structure:
The drug-polistirex complex is formed with the active ingredient (carbinoxamine maleate, USP) and sodium polystyrene sulfonate, USP, which has the following structure:
What does Karbinal look like?








What are the available doses of Karbinal?
Extended-Release Oral Suspension: 4 mg carbinoxamine maleate per 5 mL ()
What should I talk to my health care provider before I take Karbinal?
How should I use Karbinal?
Karbinal ER Extended-release Oral Suspension is an H receptor antagonist indicated for the symptomatic treatment of:
The dosage of Karbinal ER should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated.
Administer Karbinal ER by the oral route only. Measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. []
Adults and Adolescents 12 years of age and older:
7.5 mL to 20 mL (6 to 16 mg) every 12 hours
Children 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day):
2 to 3 years: 3.75 mL to 5 mL (3 to 4 mg) every 12 hours
4 to 5 years: 3.75 mL to 10 mL (3 to 8 mg) every 12 hours
6 to 11 years: 7.5 mL to 15 mL (6 to 12 mg) every 12 hours
What interacts with Karbinal?
Sorry No Records found
What are the warnings of Karbinal?
Sorry No Records found
What are the precautions of Karbinal?
Sorry No Records found
What are the side effects of Karbinal?
Sorry No records found
What should I look out for while using Karbinal?
Children younger than 2 years of age ()
Nursing mothers ()
Patients with known hypersensitivity to the drug or any of the inactive ingredients ( and )
Monoamine oxidase inhibitors (MAOI) ( and )
What might happen if I take too much Karbinal?
Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropine-like signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
The treatment of overdosage consists of discontinuation of Karbinal ER and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.
How should I store and handle Karbinal?
Karbinal ER contains 4 mg carbinoxamine maleate per 5 mL. It is a light beige to tan viscous suspension with strawberry banana flavor and is supplied as follows:NDC 23594-101-05 Bottles of 16 fl oz (480 mL)NDC 23594-101-01 Bottles of 1 fl oz (30 mL) Physician SamplesKarbinal ER contains 4 mg carbinoxamine maleate per 5 mL. It is a light beige to tan viscous suspension with strawberry banana flavor and is supplied as follows:NDC 23594-101-05 Bottles of 16 fl oz (480 mL)NDC 23594-101-01 Bottles of 1 fl oz (30 mL) Physician Samples
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Carbinoxamine is an H receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties.
Antihistamines compete with histamine for receptor sites on effector cells.
Non-Clinical Toxicology
Children younger than 2 years of age ()Nursing mothers ()
Patients with known hypersensitivity to the drug or any of the inactive ingredients ( and )
Monoamine oxidase inhibitors (MAOI) ( and )
In vitro
In an interaction study in healthy volunteers, entacapone did not significantly change the plasma levels of S-warfarin while the AUC for R-warfarin increased on average by 18% [Cl90 11% to 26%], and the INR values increased on average by 13% [Cl90 6% to 19%]. Nevertheless, cases of significantly increased INR in patients concomitantly using warfarin have been reported during the postapproval use of Comtan. Therefore, monitoring of INR is recommended when entacapone treatment is initiated or when the dose is increased for patients receiving warfarin.
Deaths have been reported in children less than 2 years of age who were taking carbinoxamine-containing drug products; therefore, Karbinal ER is contraindicated in children younger than 2 years of age.
Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities [].
The most frequent adverse reactions include: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. In clinical use, younger children and older adults may be particularly sensitive to adverse reactions [].
The following adverse reactions, listed by body system, have been identified in case reports and during the use of carbinoxamine in observational studies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole
Cardiovascular
Central Nervous System
Gastrointestinal
Hematologic
Laboratory
Respiratory
Urogenital
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).